Darunavir CAS 206361-99-1 Hoʻomaʻemaʻe Anti-HIV ≥99.0% API Hoʻomaʻemaʻe kiʻekiʻe HIV Protease Inhibitor
Mea Hana HanaNā huahana pili ʻo Darunavir:
Darunavir CAS 206361-99-1
Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Inoa Kimia | ʻO Darunavir |
| Nā huaʻōlelo like | TMC114;UIC-94017 |
| Helu CAS | 206361-99-1 |
| Helu CAT | RF-API68 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C27H37N3O7S |
| Kaumaha Molecular | 547.66 |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a i ʻole ke keʻokeʻo Crystalline pauda |
| ʻIkepili | MS/HNMR HPLC |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia i DMSO, hiki ke hoʻoheheʻe ʻia i ka wai |
| Lae hehee | 74.0~76.0 ℃ |
| ʻIkepili | 1H NMR |
| Maʻemaʻe / Kaʻina Hanana | ≥99.0% (HPLC) |
| Na mea pili | |
| Max Hoʻokahi haumia | ≤0.30% |
| Huina paumaele | ≤1.0% |
| Nā mea hoʻoheheʻe koena | Ethanol ≤0.30% |
| Nalo ma ka maloo | ≤0.50% |
| Koena ma ka Ignition | ≤0.10% |
| Nā Metala Kaumaha | ≤20ppm |
| Arsenic | ≤1.5ppm |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | Darunavir (CAS 206361-99-1) HIV-1 Protease Inhibitor Anti-HIV |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO Darunavir (inoa inoa ʻo Prezista, i kapa mua ʻia ʻo TMC114) he lāʻau lapaʻau protease inhibitor i hoʻohana ʻia e mālama i ka maʻi HIV.ʻO Darunavir kahi koho lapaʻau i manaʻo ʻia e OARAC no ka mālama ʻana-naive a me ka mālama ʻana i nā pākeke a me nā ʻōpio.ʻO Darunavir kahi ʻano hou o ka non peptide anti retroviral protease inhibitors i ka maʻi AIDS.Hoʻokumu mua ʻia e ka lālā ʻo Johnson pharmaceutical Iceland, Tibotec.ʻO ia ka bioavailability kiʻekiʻe loa i ka 6 protease inhibitors (saquinavir, ritonavirvir, indinavir, naphthalene nelfinavir, amprenavir a me ABT378/r).Hana ia ma ka pale ʻana i ka hoʻokumu ʻia ʻana o nā mea maʻi virus hou a oʻo mai ka ʻili o nā pūnaewele hoʻokipa i hoʻopili ʻia a kāohi i ka protease o ka maʻi.Ke hoʻohana ʻia ka huahana no ka manawa lōʻihi, hiki iā ia ke hōʻemi i ka vector virus HIV i ke koko, hoʻonui i ka helu o nā cell CD4, hoʻemi i ka manawa o ka maʻi HIV, hoʻomaikaʻi i ka maikaʻi o ke ola a hoʻolōʻihi i ke ola.He kūpono ia no nā mākua i loaʻa i ka maʻi HIV akā ʻaʻohe hopena i ka hoʻohana ʻana i nā lāʻau antiretroviral i loaʻa.Pono e hui pū ʻia ka lāʻau lapaʻau me ka hoʻohana ʻana i nā haʻahaʻa haʻahaʻa o ritonavir a i ʻole nā mea antiretroviral ʻē aʻe, i mea e hoʻomaikaʻi ai i ka pono.Hiki ke loiloi ʻia ka hana antiviral in vitro ma ke kūʻē ʻana i nā lymphocytes maʻi maʻi a me nā lymphocytes i loko o ke koko peripheral.
